Last edition
News about "CDSCO"
Pharmexcil’s iPHEX 2026 records USD 4.5-5 billion in potential business discussions, attracting buyers from 128 countries, with the next edition set for 2027.
CDSCO | 11/09/2026 | By News Bureau | 244
The Central Drugs Standard Control Organisation (CDSCO) signals smarter, risk-based pharma regulation at iPHEX 2026, calling for proportionate enforcement, simpler compliance and clearer regulatory norms.
CDSCO | 09/09/2026 | By News Bureau | 101
IP Alliance to Host 11th Advanced GMP Workshop on Quality Systems for the Next Decade
IP Alliance’s 11th Advanced GMP Workshop will focus on strengthening pharmaceutical quality systems amid evolving technology, manufacturing practices and regulatory requirements.
CDSCO | 07/09/2026 | By News Bureau | 129
Health Ministry Notifies Stricter Drug Rules against Fake Data
Union Health Ministry notifies stricter Drugs Rules, empowering licensing authorities to debar applicants submitting fake or fabricated data.
CDSCO | 07/08/2026 | By News Bureau
India to Build Future-Ready Drug Regulatory Framework: J P Nadda
India will build a future-ready drug regulatory framework, with the Central Drugs Standard Control Organisation (CDSCO) set to launch an end-to-end digital regulatory platform within 18 months.
CDSCO | 01/08/2026 | By News Bureau | 126
The Central Drugs Standard Control Organisation (CDSCO) has clarified the regulatory framework for formulation intermediates, specifying which products require central approval under the NDCT Rules, 2019 and which can be licensed by State Licensing Authorities (SLAs).
CDSCO | 25/06/2026 | By News Bureau | 159
Indian Pharmacopoeia Commission (IPC) hosts the Indian Pharmacopoeia (IP) 2026 Scientific Conclave and Interactive Session, focusing on medicine quality, impurity standards, regulatory science, and patient safety.
CDSCO | 16/05/2026 | By News Bureau | 202
CDSCO Cracks Down on Unlicensed IVF Medical Devices
The Central Drugs Standard Control Organisation (CDSCO) has directed its zonal and sub-zonal offices, along with State Licensing Authorities (SLAs), to maintain strict vigilance against the sale of unlicensed medical devices used in In Vitro Fertilisation (IVF) and Assisted Reproductive Technology (ART) procedures.
CDSCO | 30/03/2026 | By Darshana | 238
CDSCO Approves AstraZeneca Pharma India's Durvalumab for uHCC Treatment
AstraZeneca Pharma India has received CDSCO approval for durvalumab to treat unresectable hepatocellular carcinoma (uHCC), a major global health concern as HCC ranks among the most common and deadliest cancers worldwide.
CDSCO | 18/03/2026 | By Akanki | 182
ACC Extends Dr Rajeev Singh Raghuvanshi's appointment as Drugs Controller (India) for One Year
Dr Rajeev Singh Raghuvanshi receives a second one-year extension as head of CDSCO amid ongoing regulatory reforms and Schedule M implementation.
CDSCO | 02/03/2026 | By News Bureau | 1076
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy